NEW YORK (Reuters Health) Jul 16 – Lyme disease vaccine is cost effective only in the uncommon situation in which an individual is frequently exposed to ticks in a Lyme disease-endemic area, according to a report in the June issue of Arthritis & Rheumatism.
The high cost of the Lyme disease vaccine and the low risk of Lyme disease in most areas suggested to the authors the need for a cost-effectiveness analysis of the vaccine and an examination of the factors influencing its cost effectiveness.
Dr. Elizabeth Hsia and colleagues from University of Pennsylvania in Philadelphia performed a decision analysis of the cost effectiveness of Lyme disease vaccine under different assumptions of disease incidence and vaccine cost.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!